103 related articles for article (PubMed ID: 11365553)
1. FDA approves new combination treatment for hepatitis C. Food and Drug Administration.
Baker R
BETA; 1998 Jul; ():10. PubMed ID: 11365553
[TBL] [Abstract][Full Text] [Related]
2. Ribavirin approved with a big fat price.
Falkenberg J
Notes Undergr; 1998; (No 37):10-1. PubMed ID: 11365818
[TBL] [Abstract][Full Text] [Related]
3. Ribavirin approved for hepatitis C combination treatment.
James JS
AIDS Treat News; 1998 Jun; (No 297):7. PubMed ID: 11365595
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis C: FDA public meeting on peginterferon plus ribavirin, Nov. 14.
AIDS Treat News; 2002 Oct; (384):5. PubMed ID: 12434764
[No Abstract] [Full Text] [Related]
5. Hepatitis C: new treatment overview.
Stoia J
AIDS Treat News; 1998 Sep; (302):5-6. PubMed ID: 11365763
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis C virus infection.
Bacon BR; Di Bisceglie AM
N Engl J Med; 2001 Nov; 345(19):1425-6; author reply 1427-8. PubMed ID: 11794183
[No Abstract] [Full Text] [Related]
7. Successful treatment of fulminant hepatitis C by therapy with alpha interferon and ribavirin.
Yu ML; Hou NJ; Dai CY; Chang WY; Chuang WL
Antimicrob Agents Chemother; 2005 Sep; 49(9):3986-7. PubMed ID: 16127091
[No Abstract] [Full Text] [Related]
8. Can science meet the challenges of the HCV pandemic: new treatment options for chronic hepatitis C.
Roehr B
J Int Assoc Physicians AIDS Care; 1998 Jul; 4(7):24-9. PubMed ID: 11365638
[TBL] [Abstract][Full Text] [Related]
9. Marketing scam spoils hep C treatment.
Proj Inf Perspect; 1998 Dec; (26):6. PubMed ID: 11366498
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis C important treatment advance: interview with Douglas Dieterich, M.D. Interview by John S. James.
Dieterich D
AIDS Treat News; 1998 May; (No 295):1-5. PubMed ID: 11365406
[TBL] [Abstract][Full Text] [Related]
11. Sequential versus concomitant administration of ribavirin and interferon alfa-n3 in patients with chronic hepatitis C not responding to interferon alone: results of a randomized, controlled trial.
Sostegni R; Ghisetti V; Pittaluga F; Marchiaro G; Rocca G; Borghesio E; Rizzetto M; Saracco G
Hepatology; 1998 Aug; 28(2):341-6. PubMed ID: 9695995
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis C and HIV: ribavirin plus interferon study recruiting.
AIDS Treat News; 1998 May; (No 295):5. PubMed ID: 11365407
[TBL] [Abstract][Full Text] [Related]
13. Combination therapy for hepatitis C infection.
Newman TB
N Engl J Med; 1999 Apr; 340(15):1207; author reply 1208-9. PubMed ID: 10206843
[No Abstract] [Full Text] [Related]
14. New opportunities for the management and therapy of hepatitis C in correctional settings.
Martin CK; Hostetter JE; Hagan JJ
Am J Public Health; 2010 Jan; 100(1):13-7. PubMed ID: 20007626
[TBL] [Abstract][Full Text] [Related]
15. A small percentage of patients with hepatitis C receive triple therapy with boceprevir or telaprevir.
Chen EY; Sclair SN; Czul F; Apica B; Dubin P; Martin P; Lee WM
Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1014-20.e1-2. PubMed ID: 23602817
[TBL] [Abstract][Full Text] [Related]
16. [New drugs for hepatitis C].
Färkkilä M
Duodecim; 2014; 130(18):1813-22. PubMed ID: 25558623
[TBL] [Abstract][Full Text] [Related]
17. Combination antiviral therapy with ribavirin and interferon alfa in interferon alfa relapsers and non-responders: Italian experience.
Brillanti S; Miglioli M; Barbara L
J Hepatol; 1995; 23 Suppl 2():13-5; discussion 15-6. PubMed ID: 8720288
[TBL] [Abstract][Full Text] [Related]
18. Advances in the treatment of hepatitis C.
Lawrence SP
Adv Intern Med; 2000; 45():65-105. PubMed ID: 10635046
[TBL] [Abstract][Full Text] [Related]
19. FDA approves Hep C drugs.
AIDS Alert; 2004 Jun; 19(6):71. PubMed ID: 15272452
[No Abstract] [Full Text] [Related]
20. Analysis of ribavirin mutagenicity in human hepatitis C virus infection.
Chevaliez S; Brillet R; Lázaro E; Hézode C; Pawlotsky JM
J Virol; 2007 Jul; 81(14):7732-41. PubMed ID: 17494069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
